TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04389632: A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

Sponsor: Seagen, a wholly owned subsidiary of Pfizer · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 1006 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,346,032

Rescue Site Savings

+$4,178,328

Unlock Full NCT04389632 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04389632 Rescue Dossier →